Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eslicarbazepine Acetate as Adjunctive Therapy in Adult Focal-Onset Epilepsy
CTR20220017Phase 3Completed
- Sponsor
- Changzhou Pharmaceutical Factory
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of eslicarbazepine acetate in epilepsy, sponsored by Changzhou Pharmaceutical Factory. Started Jan 2022; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on CTR20220017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220017.